Home
Resources
Follow portfolio news
...

Biopharmaceuticals: WuXi Biologics now manages 817 projects

Published on
12/2/2025
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
Wuxi Biologics
In 2024, Wuxi Biologics added 151 new projects to its portfolio, reaching a total of 817 active projects. Our CRDMO (Contract Research, Development and Manufacturing) model enables us to support our customers at every stage of new drug development.
By
Charles Pinsolle
Charles Pinsolle
Biopharmaceuticals: WuXi Biologics now manages 817 projects
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

Growth driven by customer confidence

WuXi Biologics, a company present in the Vintage Altaroc Odyssey 2021, applies two key strategies: "Follow the Molecule", which consists of accompanying a drug throughout its development, and "Win the Molecule", which aims to win advanced and commercial projects. Thanks to these approaches, the company is growing rapidly, with over 50% of its new projects coming from the USA.

In 2024, the company also strengthened its manufacturing capabilities, notably with the use of single-use bioreactors, which improve drug production and reduce costs.

Reinforced global manufacturing

WuXi Biologics is expanding its production network in Europe and the United States. Its new site in Worcester, USA, is designed as a factory of the future, with state-of-the-art automated equipment. With its extensive production capacity and 99% batch success rate, the company is establishing itself as a key player in the sector.

A strong commitment to the environment

WuXi Biologics is also committed to sustainability. The company has received several awards for its environmental efforts and has been recognized by the United Nations for its solutions reducing the carbon footprint of biopharmaceutical players by 80%.

With solid growth and a strategy focused on innovation and ecology, WuXi Biologics continues to expand and strengthen its role in the biologics industry.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Rest of the world
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.